CY
CYAN.US Cyanotech Corporation
- Market cap
- USD 4.28M
- P/E
- -
- P/B
- 0.56x
- ROE
- 14.4%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 1 quarter up to Jun 2026.
Is CYAN.US undervalued?
Graham numberThe Graham number of Cyanotech Corporation cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Cyanotech Corporation fundamental analysis
No fundamental analysis for Cyanotech Corporation yet.
Cyanotech Corporation stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Cyanotech Corporation
Cyanotech Corporation, an agricultural company, engages in the production and sale of natural ingredients and dietary supplement products from microalgae for health and wellness markets. The company offers BioAstin Hawaiian Astaxanthin, a natural antioxidant to enhance skin, and to support eye, joint, brain, and immune health; and Hawaiian Spirulina Pacifica, a nutrient-rich dietary supplement to support natural energy, immune system, and cardiovascular health, as well as a …
Full company profileCyanotech Corporation financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 1 quarter up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Cyanotech Corporation annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 32.0M | 34.1M | 30.2M | 31.9M | 32.3M | 36.0M | 23.2M | 23.1M | 24.2M | 26.6M | 25.9M |
| Gross Profit | 12.2M | 13.4M | 10.5M | 12.7M | 11.1M | 13.6M | 7.26M | 5.95M | 6.88M | 8.67M | 11.0M |
| Operating Income | -682K | 1.41M | -3.00M | 1.05M | 84.0K | 2.57M | -2.92M | -4.59M | -2.51M | -574K | 1.81M |
| EBITDA | 1.30M | 3.29M | -1.09M | 3.28M | 3.54M | 4.50M | -825K | -2.51M | -629K | 1.31M | 3.38M |
| Net Income | -1.22M | 1.03M | -3.60M | 387K | 920K | 2.15M | -3.44M | -5.27M | -3.20M | -1.28M | 1.15M |
| EPS | -0.21 | 0.18 | -0.62 | 0.06 | 0.15 | 0.35 | -0.55 | -0.81 | -0.45 | -0.18 | 0.16 |
| Balance Sheet | |||||||||||
| Total Assets | 29.2M | 29.7M | 29.6M | 31.8M | 30.9M | 32.0M | 29.7M | 25.1M | 23.5M | 22.1M | 21.9M |
| Total Liabilities | 12.6M | 11.6M | 14.7M | 15.9M | 13.8M | 12.6M | 13.4M | 13.3M | 14.6M | 14.5M | 13.9M |
| Shareholders' Equity | 16.6M | 18.1M | 14.9M | 15.8M | 17.0M | 19.5M | 16.3M | 11.8M | 8.88M | 7.66M | 7.99M |
| Cash & Short-term Investments | 1.41M | 1.33M | 840K | 2.42M | 3.77M | 2.59M | 974K | 707K | 257K | 810K | 1.09M |
| Total Debt | 7.48M | 6.95M | 8.12M | 12.6M | 10.9M | 9.00M | 11.2M | 10.9M | 11.6M | 11.6M | 11.4M |
| Cash Flow | |||||||||||
| Operating Cash Flow | 1.22M | 1.49M | -847K | 1.24M | 2.40M | 2.38M | -2.10M | -455K | -1.19M | 234K | 1.69M |
| Capital Expenditure | 847K | 1.01M | 431K | 224K | 760K | 1.27M | 1.07M | 381K | 247K | 142K | 236K |
| Free Cash Flow | 373K | 485K | -1.28M | 1.02M | 1.64M | 1.11M | -3.17M | -836K | -1.44M | 92.0K | 1.46M |
| Ratios | |||||||||||
| ROE | -7.3% | 5.7% | -24.1% | 2.4% | 5.4% | 11.1% | -21.0% | -44.6% | -36.1% | -16.7% | 14.4% |
| ROA | -4.2% | 3.5% | -12.1% | 1.2% | 3.0% | 6.7% | -11.6% | -21.0% | -13.6% | -5.8% | 5.3% |
| Net Profit Margin | -3.8% | 3.0% | -11.9% | 1.2% | 2.8% | 6.0% | -14.8% | -22.8% | -13.2% | -4.8% | 4.5% |
| Debt to Equity | 0.45x | 0.38x | 0.54x | 0.79x | 0.64x | 0.46x | 0.68x | 0.92x | 1.30x | 1.51x | 1.42x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Cyanotech Corporation dividends
- Dividend yield
- -
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- -
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2026 | - | - | - |
| 2025 | - | - | - |
| 2024 | - | - | - |
| 2023 | - | - | - |
| 2022 | - | - | - |
| 2021 | USD 7.00K | 0.00 | 0.8% |
| 2020 | USD 31.0K | 0.01 | 8.0% |
| 2019 | USD 32.0K | 0.01 | - |
| 2018 | - | - | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 1:4 on Nov 6, 2006.
Who owns Cyanotech Corporation
- Insiders 30.98%
- Institutions 0.00%
- Public & others 69.02%
- Shares outstanding 7.25M
- Free float 4.85M
Top funds holding CYAN.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| SSgA U.S. Extended Market Index Class I | 2.76K | 0.04% | 0.00% | Dec 2023 |
| NT US Market Cap Idx Fd - L | 340.00 | 0.00% | 0.00% | Dec 2023 |
Top institutions holding CYAN.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Northern Trust Investments N A | 0.00 | 0.00% | -100.00% | Dec 2024 |
Cyanotech Corporation company profile
- Company name
- Cyanotech Corporation
- Ticker
- CYAN.US
- Exchange
- USA Stocks
- Listed since
- Jun 22, 1993
- Sector
- Consumer Defensive
- Industry
- Personal Care Products
- Employees
- 83
- Fiscal year end
- March
- Address
- 73-4460 Queen Kaahumanu Highway, Kailua-Kona, HI, United States, 96740
- Phone
- 808 326 1353
- Website
- cyanotech.com
About Cyanotech Corporation
Cyanotech Corporation, an agricultural company, engages in the production and sale of natural ingredients and dietary supplement products from microalgae for health and wellness markets. The company offers BioAstin Hawaiian Astaxanthin, a natural antioxidant to enhance skin, and to support eye, joint, brain, and immune health; and Hawaiian Spirulina Pacifica, a nutrient-rich dietary supplement to support natural energy, immune system, and cardiovascular health, as well as a source of protein, antioxidant carotenoids, and essential nutrients. It also provides contract extraction, and research and development services. The company sells its products through distributors, retailers, and online channels; direct to consumers; and in bulk form to manufacturers, formulators, and distributors in the health food, cosmetic manufacturers and nutraceuticals, and dietary supplement markets. It operates in the United States, the Asia-Pacific, Europe, and internationally. Cyanotech Corporation was incorporated in 1983 and is headquartered in Kailua-Kona, Hawaii.
Cyanotech Corporation management
7- Mr. Matthew Keith CusterPresident, CEO & Director · born 1983
- Dr. Gerald R. Cysewski Ph.D.Co-Founder, CEO Emeritus & Chief Scientific Officer · born 1949
- Ms. Jennifer MiyashiroCFO, VP of Finance & Administration and Treasurer · born 1981
- Mr. Glenn D. JensenVice President of Operations · born 1958
- Ms. Jennifer K. BrandVice President of Sales · born 1973
- Ms. Amy Beth NordinVP of HR & Corporate Secretary · born 1969
- Ms. Collette N. KakukChief Strategic & Commercial Officer · born 1971